scholarly article | Q13442814 |
P356 | DOI | 10.1159/000104150 |
P698 | PubMed publication ID | 17595512 |
P50 | author | Wolfgang Wick | Q2591750 |
Michael Weller | Q2779469 | ||
P2093 | author name string | Johannes Rieger | |
Brigitte Frank | |||
P433 | issue | 1-4 | |
P921 | main subject | TNF | Q18032037 |
P304 | page(s) | 23-34 | |
P577 | publication date | 2007-01-01 | |
P1433 | published in | Cellular Physiology and Biochemistry | Q2229420 |
P1476 | title | Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand | |
P478 | volume | 20 |
Q54605968 | A-172 |
Q54817124 | D-247MG |
Q54902768 | LN-18 |
Q54902771 | LN-229 |
Q54902775 | LN-308 |
Q54902776 | LN-319 |
Q54902783 | LN-428 |
Q52609889 | T98G |
Q107117135 | Tu-107 |
Q54973298 | Tu-113 |
Q54973306 | Tu-132 |
Q54973308 | Tu-140 |
Q107117136 | Tu-159 |
Q54973513 | U-138MG |
Q54973550 | U-251MG |
Q54973575 | U-373MG ATCC |
Q7863603 | U-87MG ATCC |
Q36692259 | 5,7-Dihydroxyflavone Enhances the Apoptosis-Inducing Potential of TRAIL in Human Tumor Cells via Regulation of Apoptosis-Related Proteins |
Q34722539 | APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo |
Q38960128 | Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors |
Q64987315 | Engineered human mesenchymal stem cells for neuroblastoma therapeutics. |
Q34474267 | Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas |
Q33828114 | Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. |
Q35783593 | Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition. |
Q36512525 | Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors |
Q37585453 | Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma |
Q34132999 | Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo |
Q37403279 | Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity |
Q37356520 | Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide |